



GCP INSPECTION STATEMENT

Inspection Number	INSP GCP 15140/671693-0012
Type and Purpose of Inspection	GCP Systems and Phase I Accreditation Inspection
Organisation Inspected	Hammersmith Medicines Research (HMR)
Organisation Address	Cumberland Avenue, London, NW10 7EW
Organisation Type	Phase I CRO
Dates of Inspection	20th – 23rd August 2018
Lead Inspector	Gail Francis, Expert Inspector, GCP
Accompanying Inspector(s)	Andy Fisher, Lead Senior GCP Inspector
Date of Inspection Statement	7 th November 2018

The organisation has provided corrective and preventative actions in response to the inspection report. These have been reviewed by the GCP Inspectorate and are considered acceptable. This inspection can be considered closed.

In summary:

There were no “critical” findings identified during this inspection.

There were no “major” findings identified during this inspection

The factual matter contained in the GCP Inspection Report relates only to those things that the Inspection team saw and heard during the inspection process. The GCP Inspection Report and Inspection Statement are not to be taken as implying a satisfactory state of affairs in documentation, premises, equipment, personnel or procedures not examined on this occasion.

Statement Issued by

Gail Francis

Expert GCP Inspector, MHRA